Impact of temozolomide on immune response during malignant glioma chemotherapy

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Sengupta, Sadhak ^a,b   Marrinan, Jaclyn ^a   Frishman, Caroline ^a   Sampath, Prakash ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIFE EXPECTANCY; LYMPHOCYTOPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; BRAIN TUMOR; DRUG RESISTANCE; GLIOMA; IMMUNOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84870203116     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/831090     Document Type: Review

References (84)

1. Central Brain Tumor Registry of the United States (CTBRUS) Report 2010. http://www.cbtrus.org/factsheet/factsheet.html
2. Stupp R., Mason W. P., Van Den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330 (Pubitemid 40349501)
3. DeAngelis L. M., Brain tumors. The New England Journal of Medicine 2001 344 2 114 123 2-s2.0-0035843243 10.1056/NEJM200101113440207 (Pubitemid 32052502)
4. Laws E. R., Parney I. F., Huang W., Anderson F., Morris A. M., Asher A., Lillehei K. O., Bernstein M., Brem H., Sloan A., Berger M. S., Chang S., Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. Journal of Neurosurgery 2003 99 3 467 473 2-s2.0-0042922753 (Pubitemid 37040405)
5. Wainwright D. A., Nigam P., Thaci B., Recent developments on immunotherapy for brain cancer. Expert Opinions in Emerging Drugs 2012 17 2 181 202 10.1517/14728214.2012.679929
6. Rolle C. E., Sengupta S., Lesniak M. S., Mechanisms of immune evasion by gliomas. Advances in Experimental Medicine and Biology 2012 746 53 76 10.1007/978-1-4614-3146-65
7. Wainwright D. A., Sengupta S., Han Y., Ulasov I. V., Lesniak M. S., The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human gliom. PLoS ONE 2010 5 10 2-s2.0-78149453343 10.1371/journal.pone.0015390 e15390
8. Sengupta S., Nandi S., Hindi E. S., Wainwright D. A., Han Y., Lesniak M. S., Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 2010 12 10 837 847 2-s2.0-77957773443 10.1593/neo.10662
9. Donato V., Papaleo A., Castrichino A., Banelli E., Glangaspero F., Salvati M., Delfini R., Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007 93 3 248 256 2-s2.0-34447534387 (Pubitemid 47080010)
10. Jalali R., Basu A., Gupta T., Munshi A., Menon H., Sarin R., Goel A., Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. British Journal of Neurosurgery 2007 21 6 583 587 2-s2.0-37049006734 10.1080/02688690701604574 (Pubitemid 350249205)
11. Rolle C. E., Sengupta S., Lesniak M. S., Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurgery Clinics of North America 2010 21 1 201 214 2-s2.0-70450196586 10.1016/j.nec.2009.08.002
12. Stupp R., Hegi M. E., Mason W. P., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology 2009 10 5 459 466 10.1016/S1470-2045(09)70025-7
13. American Cancer Society, Brain and Spinal Cord Tumors in Children 2010 Atlanta, Ga, USA
14. FDA Approval for Temozolomide,. National Cancer Institute, 2010, http://www.cancer.gov/cancertopics/druginfo/fda-temozolomide
15. Mrugala M. M., Chamberlain M. C., Hutchinson F., Mechanisms of disease: temozolomide and glioblastoma-look to the future. Nature Clinical Practice Oncology 2008 5 8 476 486 2-s2.0-48649086682 10.1038/ncponc1155
16. Mirimanoff R. O., Gorlia T., Mason W., Van Den Bent M. J., Kortmann R. D., Fisher B., Reni M., Brandes A. A., Curschmann J., Villa S., Cairncross G., Allgeier A., Lacombe D., Stupp R., Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of Clinical Oncology 2006 24 16 2563 2569 2-s2.0-33745010017 10.1200/JCO.2005.04.5963 (Pubitemid 46630635)
17. Ashby L. S., Ryken T. C., Management of malignant glioma: steady progress with multimodal approaches. Neurosurgical Focus 2006 20 4 E3 2-s2.0-33747151646 10.3171/foc.2006.20.4.2
18. Carpentier A. F., Meng Y., Recent advances in immunotherapy for human glioma. Current Opinion in Oncology 2006 18 6 631 636 2-s2.0-33748889305 10.1097/01.cco.0000245321.34658.f4 (Pubitemid 44427639)
19. Trinh V. A., Patel S. P., Hwu W. J., The safety of temozolomide in the treatment of malignancies. Expert Opinion on Drug Safety 2009 8 4 493 499 2-s2.0-67650526463 10.1517/14740330902918281
20. Sampson J. H., Aldape K. D., Archer G. E., Coan A., Desjardins A., Friedman A. H., Friedman H. S., Gilbert M. R., Herndon J. E., McLendon R. E., Mitchell D. A., Reardon D. A., Sawaya R., Schmittling R., Shi W., Vredenburgh J. J., Bigner D. D., Heimberger A. B., Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology 2011 13 3 324 333 2-s2.0-79955784386 10.1093/neuonc/noq157
21. De Gast G. C., Batchelor D., Kersten M. J., Vyth-Dreese F. A., Sein J., Van De Kasteele W. F., Nooijen W. J., Nieweg O. E., De Waal M. A., Boogerd W., Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN α in patients with metastatic melanoma. British Journal of Cancer 2003 88 2 175 180 2-s2.0-0037468096 10.1038/sj.bjc.6600717 (Pubitemid 36255832)
22. Denny B. J., Wheelhouse R. T., Stevens M. F. G., Tsang L. L. H., Slack J. A., NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994 33 31 9045 9051 2-s2.0-0028133013 (Pubitemid 24272851)
23. 6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents. Cancer Research 2005 65 8 3319 3327 2-s2.0-17144431814 (Pubitemid 40524616)
24. Trivedi R. N., Almeida K. H., Fornsaglio J. L., Schamus S., Sobol R. W., The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Research 2005 65 14 6394 6400 2-s2.0-22244448679 10.1158/0008-5472.CAN-05-0715 (Pubitemid 40994427)
25. Donson A. M., Addo-Yobo S. O., Handler M. H., Gore L., Foreman N. K., MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatric Blood and Cancer 2007 48 4 403 407 2-s2.0-33847364433 10.1002/pbc.20803 (Pubitemid 46340105)
26. 6-methylguanine. Oncogene 2007 26 2 186 197 2-s2.0-33846252663 10.1038/sj.onc.1209785 (Pubitemid 46095730)
27. Hegi M. E., Diserens A. C., Gorlia T., Hamou M. F., De Tribolet N., Weller M., Kros J. M., Hainfellner J. A., Mason W., Mariani L., Bromberg J. E. C., Hau P., Mirimanoff R. O., Cairncross J. G., Janzer R. C., Stupp R., MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine 2005 352 10 997 1003 2-s2.0-20044372154 10.1056/NEJMoa043331 (Pubitemid 40349502)
28. 6-alkylguanine-DNA alkyltransferase. Progress in Nucleic Acid Research and Molecular Biology 1995 51 167 223 2-s2.0-0028794564
29. Dolan M. E., Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. Advanced Drug Delivery Reviews 1997 26 2-3 105 118 2-s2.0-0031558241 10.1016/S0169-409X(97)00028-8 (Pubitemid 27289528)
30. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study. Journal of Clinical Oncology 1998 16 10 3310 3315 2-s2.0-0031595389 (Pubitemid 28481626)
31. Gerson S. L., Clinical relevance of MGMT in the treatment of cancer. Journal of Clinical Oncology 2002 20 9 2388 2399 2-s2.0-0036570062 10.1200/JCO.2002.06.110 (Pubitemid 34441669)
32. Happold C., Roth P., Wick W., Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 2012. In press 10.1111/j.1471-4159.2012.07781.x
33. 6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen. Cell Biochemistry and Biophysics 2012 62 1 185 191 10.1007/s12013-011-9280-7
34. Jiang G., Wei Z. P., Pei D. S., Xin Y., Liu Y. Q., Zheng J. N., A novel approach to overcome temozolomide resistance in glioma and melanoma: inactivation of MGMT by gene therapy. Biochemical and Biophysical Research Communications 2011 406 3 311 314 2-s2.0-79952739967 10.1016/j.bbrc.2011.02.042
35. Van Nifterik K. A., Van Den Berg J., Van Der Meide W. F., Ameziane N., Wedekind L. E., Steenbergen R. D. M., Leenstra S., Lafleur M. V. M., Slotman B. J., Stalpers L. J. A., Sminia P., Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. British Journal of Cancer 2010 103 1 29 35 2-s2.0-77954176766 10.1038/sj.bjc.6605712
36. 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Japanese Journal of Clinical Oncology 2007 37 12 897 906 2-s2.0-38749146312 10.1093/jjco/hym132 (Pubitemid 351176479)
37. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. Journal of Neurochemistry 2006 96 3 766 776 2-s2.0-33645105856 10.1111/j.1471-4159.2005. 03583.x
38. Kitange G. J., Carlson B. L., Schroeder M. A., Grogan P. T., Lamont J. D., Decker P. A., Wu W., James C. D., Sarkaria J. N., Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-Oncology 2009 11 3 281 291 2-s2.0-67649610349 10.1215/15228517-2008-090
39. Riemenschneider M. J., Hegi M. E., Reifenberger G., MGMT promoter methylation in malignant gliomas. Targeted Oncology 2010 5 3 161 165 2-s2.0-78049317939 10.1007/s11523-010-0153-6
40. Zhang J., Stevens M. F. G., Laughton C. A., Madhusudan S., Bradshaw T. D., Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010 78 2 103 114 2-s2.0-77950059191 10.1159/000306139
41. Brock C. S., Newlands E. S., Wedge S. R., Bower M., Evans H., Colquhoun I., Roddie M., Glaser M., Brampton M. H., Rustin G. J. S., Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Research 1998 58 19 4363 4367 2-s2.0-0032188739 (Pubitemid 28450038)
42. 6-Benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity. Journal of Pharmacology and Experimental Therapeutics 1999 291 3 1292 1300 2-s2.0-0032732618
43. Khan R. B., Raizer J. J., Malkin M. G., Bazylewicz K. A., Abrey L. E., A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 2002 4 1 39 43 2-s2.0-0036208462 10.1215/S1522851701000382 (Pubitemid 34269465)
44. Heimberger A. B., Sun W., Hussain S. F., Dey M., Crutcher L., Aldape K., Gilbert M., Hassenbusch S. J., Sawaya R., Schmittling B., Archer G. E., Mitchell D. A., Bigner D. D., Sampson J. H., Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro-Oncology 2008 10 1 98 103 2-s2.0-39149097490 10.1215/15228517-2007-046 (Pubitemid 351250906)
45. Vestermark L. W., Holtved E., Dahlrot R., A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response. Ecancermedicalscience 2008 2, article 91
46. Stupp R., Dietrich P. Y., Kraljevic S. O., Pica A., Maillard I., Maeder P., Meuli R., Janzer R., Pizzolato G., Miralbell R., Porchet F., Regli L., De Tribolet N., Mirimanoff R. O., Leyvraz S., Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Journal of Clinical Oncology 2002 20 5 1375 1382 2-s2.0-0036499085 10.1200/JCO.20.5.1375 (Pubitemid 34177445)
47. 6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Annals of Oncology 1999 10 7 831 838 2-s2.0-0032793312 10.1023/A:1008304032421 (Pubitemid 29368001)
48. Briegert M., Kaina B., Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Research 2007 67 1 26 31 2-s2.0-33846419805 10.1158/0008-5472.CAN-06-3712 (Pubitemid 46142756)
49. Briegert M., Enk A. H., Kaina B., Change in expression of MGMT during maturation of human monocytes into dendritic cells. DNA Repair 2007 6 9 1255 1263 2-s2.0-34547805294 10.1016/j.dnarep.2007.02.008 (Pubitemid 47238680)
50. Zhu X., Fujita M., Snyder L. A., Okada H., Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. Journal of Neuro-Oncology 2011 104 1 83 92 2-s2.0-78649319875 10.1007/s11060-010-0473-5
51. Desbaillets I., Tada M., De Tribolet N., Diserens A. C., Hamou M. F., Van Meir E. G., Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. International Journal of Cancer 1994 58 2 240 247 2-s2.0-0027959172 10.1002/ijc.2910580216 (Pubitemid 24240102)
52. Leung S. Y., Wong M. P., Chung L. P., Chan A. S. Y., Yuen S. T., Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathologica 1997 93 5 518 527 2-s2.0-0030951515 10.1007/s004010050647 (Pubitemid 27186993)
53. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G. M., Feng Z. H., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Letters 2007 252 1 86 92 2-s2.0-34248328368 10.1016/j.canlet.2006.12.012 (Pubitemid 46734559)
54. Bauer M., Goldstein M., Heylmann D., Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLoS ONE 2012 7 6 e39956
55. Fadul C. E., Fisher J. L., Gui J., Hampton T. H., Côté A. L., Ernstoff M. S., Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-Oncology 2011 13 4 393 400 2-s2.0-79955767478 10.1093/neuonc/noq204
56. Banissi C., Ghiringhelli F., Chen L., Carpentier A. F., Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunology, Immunotherapy 2009 58 10 1627 1634 2-s2.0-68549112974 10.1007/s00262-009-0671-1
57. + lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. Journal of Clinical Oncology 2004 22 4 610 616 2-s2.0-1442283179 10.1200/JCO.2004.07.060 (Pubitemid 41095063)
58. Mitchell D. A., Cui X., Schmittling R. J., Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011 118 11 3003 3012 10.1182/blood-2011-02- 334565
59. Sampson J. H., Schmittling R. J., Archer G. E., A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS ONE 2012 7 2 e31046
60. North R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. Journal of Experimental Medicine 1982 155 4 1063 1074 2-s2.0-0020047427 (Pubitemid 12142723)
61. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology 2005 23 10 2346 2357 2-s2.0-20244366111 10.1200/JCO.2005.00.240 (Pubitemid 46218728)
62. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 298 5594 850 854 2-s2.0-0037174674 10.1126/science.1076514 (Pubitemid 35231542)
63. Neyns B., Tosoni A., Hwu W. J., Reardon D. A., Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 2010 116 12 2868 2877 2-s2.0-77953983710 10.1002/cncr.25035
64. Fadul C. E., Fisher J. L., Hampton T. H., Lallana E. C., Li Z., Gui J., Szczepiorkowski Z. M., Tosteson T. D., Rhodes C. H., Wishart H. A., Lewis L. D., Ernstoff M. S., Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. Journal of Immunotherapy 2011 34 4 382 389 2-s2.0-79955591522 10.1097/CJI.0b013e318215e300
65. Kim T. G., Kim C. H., Park J. S., Park S. D., Kim C. K., Chung D. S., Hong Y. K., Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clinical and Vaccine Immunology 2010 17 1 143 153 2-s2.0-74549126817 10.1128/CVI.00292-09
66. Ishikawa E., Yamamoto T., Sakamoto N., Nakai K., Akutsu H., Tsuboi K., Takano S., Matsumura A., Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. Neurologia Medico-Chirurgica 2010 50 8 638 644 2-s2.0-77956216230 10.2176/nmc.50.638
67. Ridola V., Barone G., Lazzareschi I., Ruggiero A., Rizzo D., Riccardi R., Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. Journal of Neuro-Oncology 2011 103 1 147 153 2-s2.0-79959924879 10.1007/s11060-010-0371-x
68. Sarkaria J. N., Galanis E., Wu W., Dietz A. B., Kaufmann T. J., Gustafson M. P., Brown P. D., Uhm J. H., Rao R. D., Doyle L., Giannini C., Jaeckle K. A., Buckner J. C., Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clinical Cancer Research 2010 16 22 5573 5580 2-s2.0-78349245231 10.1158/1078-0432.CCR-10-1453
69. 6-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in Jurkat cells. Journal of Pharmacology and Experimental Therapeutics 2000 294 2 664 671 2-s2.0-0033943310 (Pubitemid 30490843)
70. 6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Molecular Therapy 2001 3 1 78 87 2-s2.0-0034990304 10.1006/mthe.2000.0223 (Pubitemid 32509808)
71. 6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro-Oncology 2009 11 1 22 32 2-s2.0-61449121090 10.1215/15228517-2008-080
72. Zielske S. P., Reese J. S., Lingas K. T., Donze J. R., Gerson S. L., In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. Journal of Clinical Investigation 2003 112 10 1561 1570 2-s2.0-0347086143 10.1172/JCI200317922 (Pubitemid 38056282)
73. Pollok K. E., Hartwell J. R., Braber A., Cooper R. J., Jansen M., Ragg S., Bailey B. J., Erickson L. C., Kreklau E. L., Williams D. A., In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Human Gene Therapy 2003 14 18 1703 1714 2-s2.0-10744232285 (Pubitemid 38010661)
74. Neff T., Beard B. C., Peterson L. J., Anandakumar P., Thompson J., Kiem H. P., Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005 105 3 997 1002 2-s2.0-12844249961 10.1182/blood-2004-08-3169 (Pubitemid 40170867)
75. Gerull S., Beard B. C., Peterson L. J., Neff T., Kiem H. P., In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Human Gene Therapy 2007 18 5 451 456 2-s2.0-34249789022 10.1089/hum.2006.039 (Pubitemid 46850136)
76. Dasgupta A., McCarty D., Spencer H. T., Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge. Biochemical and Biophysical Research Communications 2010 391 1 170 175 2-s2.0-72949113425 10.1016/j.bbrc.2009.11.026
77. 6- methylguanine-DNA methyltransferase P140K. Gene Therapy 2010 17 3 389 399 2-s2.0-77949424638 10.1038/gt.2009.133
78. Kong S., Sengupta S., Tyler B., Suppression of human glioma xenografts with 2nd generation IL13R-specific chimeric antigen receptor-modified T cells. Clinical Cancer Research, 2012. In press 10:1158/1078-0432.CCR12-0319
79. Stastny M. J., Brown C. E., Ruel C., Jensen M. C., Medulloblastomas expressing IL13R α 2 are targets for IL13-zetakine+ cytolytic T cells. Journal of Pediatric Hematology/Oncology 2007 29 10 669 677 2-s2.0-35148846429 10.1097/MPH.0b013e3181468c68 (Pubitemid 47549178)
80. Kahlon K. S., Brown C., Cooper L. J. N., Raubitschek A., Forman S. J., Jensen M. C., Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Research 2004 64 24 9160 9166 2-s2.0-10844296758 10.1158/0008-5472.CAN-04-0454 (Pubitemid 39665531)
81. Ahmed N., Ratnayake M., Savoldo B., Perlaky L., Dotti G., Wels W. S., Bhattacharjee M. B., Gilbertson R. J., Shine H. D., Weiss H. L., Rooney C. M., Heslop H. E., Gottschalk S., Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Research 2007 67 12 5957 5964 2-s2.0-34250844475 10.1158/0008-5472.CAN-06-4309 (Pubitemid 46985032)
82. Bullain S. S., Sahin A., Szentirmai O., Sanchez C., Lin N., Baratta E., Waterman P., Weissleder R., Mulligan R. C., Carter B. S., Genetically engineered T cells to target EGFRvIII expressing glioblastoma. Journal of Neuro-Oncology 2009 94 3 373 382 2-s2.0-69249248185 10.1007/s11060-009-9889-1
83. Ohno M., Natsume A., Ichiro Iwami K., Iwamizu H., Noritake K., Ito D., Toi Y., Ito M., Motomura K., Yoshida J., Yoshikawa K., Wakabayashi T., Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Science 2010 101 12 2518 2524 2-s2.0-78449281478 10.1111/j.1349-7006.2010.01734.x
84. M. C. Kizilarslanoglu, S. Aksoy, N. O. Yildirim et al., "Temozolomideelated infections: review of the literature," Journal of Balkan Union of Oncology, vol. 16, no. 3, pp. 547-550, 2011.